GYRE THERAPEUTICS, INC. Revenue Disclosure
6. |
Revenue |
The Company’s product revenues were mainly generated from the sale of ETUARY®. The Company launched two new products: Contiva® (avatrombopag maleate tablets), which commenced commercialization in March 2025, and Etorel®, which commenced commercialization in June 2025.
The following table summarizes the composition of product revenues for the years ended December 31, 2025 and 2024:
|
|
Year ended December 31, |
|
|||||||||||
Product Revenue Composition |
|
2025 |
|
|
2024 |
|
||||||||
ETUARY® |
|
$ |
106,137 |
|
|
91.0 |
% |
|
$ |
105,009 |
|
|
99.3 |
% |
Contiva® |
|
|
5,520 |
|
|
4.7 |
% |
|
|
— |
|
|
— |
% |
Etorel® |
|
|
4,619 |
|
|
4.0 |
% |
|
|
— |
|
|
— |
% |
Other Products |
|
|
312 |
|
|
0.3 |
% |
|
|
748 |
|
|
0.7 |
% |
Total |
|
$ |
116,588 |
|
|
100.0 |
% |
|
$ |
105,757 |
|
|
100.0 |
% |
Sales of Pharmaceutical Products
The Company generates revenue mostly through sales of ETUARY®, Contiva®, Etorel® and certain generic drugs. The distributors were the Company’s direct customers, and sales to distributors accounted for 100.0% of revenue. The distributors sell pharmaceutical products to outlets, including hospitals and other medical institutions, as well as pharmacies.
Product returns to date have not been significant and the Company has not considered it necessary to record a reserve for product returns. The Company’s product revenues were recognized at a point in time when the underlying product was delivered to the customer, which was when the customer obtained control of the product. All sales are generated in mainland China.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 13, 2026 | Showing above |
| 2024 | Mar 17, 2025 | |
| 2023 | Mar 27, 2024 | |
| 2022 | Mar 30, 2023 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.